Seponering på grund af kliniske eller laboratoriemæssige bivirkninger forekom mindre hyppigt for irbesartan- behandlede (3, 3%) patienter end for placebo- behandlede (4, 5%) patienter.
Discontinuation due to any clinical or laboratory adverse event was less frequent for irbesartan-treated patients (3.3%) than for placebo-treated patients (4.5%).